All women with non-mucinous ovarian cancer to be BRCA tested at diagnosis

What we want

  • All women with non-mucinous ovarian cancer to be BRCA1/2 tested at diagnosis

What we've done


  • Women with ovarian cancer have a 15-20% chance of carrying a BRCA gene mutation
  • Inheriting a faulty gene known as the BRCA1 or BRCA2 mutation creates a greater chance, 35-60%, of developing ovarian cancer
  • The Ovarian Cancer Action BRCA1/2 Gene Testing Policy Report states that trials at The Royal Marsden have demonstrated that testing can be carried out in a way that is affordable, deliverable and beneficial to women with the disease and their families
  • Knowing that you carry a BRCA gene mutation can help inform women's treatment paths and may provide trials for them to participa

    te in
  • Women who know that they carry BRCA gene mutations can also inform their families and potentially prevent future cancers or help to spot them early
  • Currently in order to qualify for BRCA1/2 testing, NICE recommends a likelihood of having inherited the genetic mutation of 10% or over, determined through looking at family history. But studies have indicated that around 50% of women diagnosed with non-mucinous epithelial ovarian cancer have no family history of the disease

How you can help